Extrait

The primary objective of the trial is to evaluate the clinical anti-tumor acitivity of EMD 525797 administered as 1-hour intravenous (i.v.) infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with asymptomatic or mildly symptomatic mCRPC.

Critère d'inclusion

• subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC)

Liens

• ictrp
• ictrp
• ictrp
• euctr
• euctr
• euctr
• euctr
• ictrp
• ictrp
• euctr